Evidence map›Paper›PMID 42435123›Full record

ReviewClinical and experimental nephrology2026

Beyond urinalysis: a review of life-course chronic kidney disease screening across health examination systems in Japan.

Kimiko Honda, Yoko Fujita, Yugo Shibagaki, Rei Goto, Yoshimitsu Gotoh, Yutaka Harita

Abstract readReview
In one paragraph

Review in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kimiko HondaGraduate School of Health Management, Keio University, Tokyo, Japan.
Yoko FujitaDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Yugo ShibagakiDivision of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
Rei GotoGraduate School of Health Management, Keio University, Tokyo, Japan.
Yoshimitsu GotohDepartment of Pediatrics, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Aichi, Japan.
Yutaka HaritaDepartment of Pediatrics, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. haritay-ped@h.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-3123-7444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a major public health problem. Most international guidelines recommend targeted testing of individuals at high risk rather than population-wide screening. In Japan, urinalysis is embedded in health examination systems across the life course. However, the existence of repeated urinalysis opportunities has not necessarily meant that these programs functioned as a coherent CKD screening pathway. Repeated urinalyses were introduced under different legal mandates and for different public health purposes, with substantial variation in target conditions, test components, and follow-up arrangements. In this context, the 2025 policy decision to add serum creatinine to workplace-based health examinations, following sustained advocacy by the Japanese Society of Nephrology and growing recognition of non-proteinuric CKD, marks an important policy turning point. This review provides an overview of Japan's current health examination systems from the perspective of CKD screening throughout the life course. Specifically, this review describes the 3-year-old health examination, school urinary screening, workplace-based health examinations, the Specific Health Checkup, and late-stage elderly medical examinations by focusing on their institutional basis, structure, follow-up pathways, and current limitations. Taken together, Japan's health examination systems provide repeated urinalyses; however, these opportunities do not automatically amount to a coherent CKD screening strategy. This overview highlights the need to clarify target conditions, downstream interventions, outcome measures, and continuity across programs.

Indexed as

Mass ScreeningRenal Insufficiency, ChronicUrinalysisHumansJapanPhysical ExaminationPredictive Value of TestsChronic kidney diseaseHealth examinationJapanLife courseScreeningUrinalysis

Identifiers

PMID42435123
PMCPMC13582210

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.